Emerging Health Economics Data Suggest Earlier LM Detection May Reduce Healthcare Costs
Leptomeningeal metastases (LM) remains one of the most challenging and resource-intensive complications in oncology, often associated with delayed diagnosis, complex management, and significant healthcare utilization.
At the upcoming ISPOR 2026 Annual Meeting, Plus Therapeutics, Inc. will present new health economics data evaluating the potential impact of earlier LM detection and management using the CNSide® Cerebrospinal Fluid (CSF) Assay.
The analysis suggests that earlier detection and therapeutic management of leptomeningeal metastases using CNSide may reduce total LM-related healthcare costs by approximately 40%, highlighting the growing importance of advanced diagnostics in neuro-oncology care pathways.
Why Earlier Detection Matters in Neuro-Oncology
Earlier identification of leptomeningeal metastases may provide clinicians with additional opportunities to initiate more timely and targeted interventions.
The CNSide® CSF Assay Platform is designed to detect and characterize tumor cells in cerebrospinal fluid, supporting diagnostic evaluation in patients with suspected LM.
Emerging evidence suggests that earlier access to actionable CSF-based tumor data may help:
- Support more confident diagnostic assessment
- Inform therapeutic planning
- Potentially reduce avoidable hospitalizations
- Decrease adverse events associated with delayed intervention
- Improve overall management of complex CNS metastatic disease
As precision medicine continues to evolve in oncology, advanced diagnostic technologies are playing an increasingly important role in helping clinicians navigate difficult-to-diagnose disease states such as LM.
The Expanding Role of CSF-Based Diagnostics in LM Management
Traditional approaches to diagnosing leptomeningeal metastases can present challenges due to the complexity of CNS disease and limitations associated with standard testing methods.
CSF-based diagnostics are emerging as an important area of innovation within neuro-oncology because they may provide additional biological insights into CNS disease involvement.
The CNSide® platform combines advanced tumor cell detection and characterization technologies designed specifically for patients with suspected leptomeningeal metastases.
As CNSide enters U.S. commercialization, the goal is to help clinicians identify and manage LM earlier and with greater confidence.
Interested in learning more or ordering a test from our lab? Contact CNSide Diagnostics
About CNSide® Diagnostics
CNSide® is a proprietary diagnostic platform designed to detect and characterize tumor cells in cerebrospinal fluid (CSF) from patients with leptomeningeal metastases. The platform combines advanced technologies to support enhanced diagnostic insights and help address unmet needs in neuro-oncology.nsights and help address unmet needs in neuro-oncology.
0 Comments